Liminatus Pharma, Inc. (LIMN) Regains Nasdaq Bid-Price Compliance After 1-for-50 Reverse Split

Liminatus Pharma, Inc. regained compliance with Nasdaq’s minimum bid price rule after effecting a 1-for-50 reverse stock split on Aug. 20, 2026. Nasdaq confirmed the bid stayed above $1 for 13 consecutive trading days ending Sept. 9, 2026.Material DetailsContext by AI AnalystThis is a late confirma…